Status: Available
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who have received and failed or been intolerant to at least one standard approved therapy and/or have no comparable or satisfactory alternative therapy options.
Trial details
Age: 18+Biological sex: AllType: Expanded AccessSponsor: Cogent Biosciences, Inc.Updated: Jul 13, 2026Locations: 23
Eligibility criteria
Able to provide written informed consent and commit to EAP assessments. [+5]
Patients who are eligible for and/or enrolled in an on-going bezuclastinib clini... [+3]